Mehmet Karaçalı
Research Subjects
Mehmet Karaçalı has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ali Erol
Bursa Specialized Training and Research Hospital, Health Sciences University, Department of Internal Medicine, Bursa, Turkey
1 shared publication - Alper Aytekin
Department of General Surgery, School of Medicine, Gaziantep University, Gaziantep 27310, Turkey
1 shared publication - Aydin Dursun
Mudanya University, Vocational School, Department of Anestesia, Bursa, Türkiye
1 shared publication - Elif Melis Baloğlu Akyol
Department of Endocrinology and Metabolism, Gaziantep City Hospital, Gaziantep 27100, Turkey
1 shared publication - Enes Kocaman
Department of Internal Medicine, Health Sciences University, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Türkiye image/svg+xml
1 shared publication - Ersin Akarsu
Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine Gaziantep University Gaziantep Turkey
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
- Vol. 32 (2) , 227-234
Consideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?
Objective: The use of medium and low-dose inhaled corticosteroids (ICS) did not increase the risk of osteoporosis in individuals with chronic obstructive pulmonary disease (COPD). The goal is to look at the risk of osteoporosis that comes with Budesonide and Fluticasone when choosing ICS for people with COPD, since this group of people is more likely to get osteoporosis. Methods: Patients with Stage E COPD who were on ICS and came to a tertiary healthcare facility between January 2024 and January 2025 were included. There were three groups in the trial: people with COPD who were taking inhaled budesonide, those who were on fluticasone, and a control group. Results: The study comprised 122 participants: 16 COPD patients utilizing inhaled fluticasone, 16 COPD patients utilizing inhaled budesonide, and 90 individuals in the control group. The mean age of the study participants was 72.79 years; the mean age of the fluticasone group was 74.69 years, the mean age of the budesonide group was 73.19 years, and the mean age of the control group was 72.38 years. The groups exhibit no significant difference for osteoporosis (p>0.05). No significant difference was seen between the groups for the duration and intensity of ICS use (p>0.05). Conclusion: In individuals with COPD, the administration of budesonide and fluticasone as inhaled corticosteroid options has not elevated the risk of osteoporosis.
- 27 March 2026
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
- Vol. 32 (2) , 227-234
Open AccessConsideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?
Objective: The use of medium and low-dose inhaled corticosteroids (ICS) did not increase the risk of osteoporosis in individuals with chronic obstructive pulmonary disease (COPD). The goal is to look at the risk of osteoporosis that comes with Budesonide and Fluticasone when choosing ICS for people with COPD, since this group of people is more likely to get osteoporosis. Methods: Patients with Stage E COPD who were on ICS and came to a tertiary healthcare facility between January 2024 and January 2025 were included. There were three groups in the trial: people with COPD who were taking inhaled budesonide, those who were on fluticasone, and a control group. Results: The study comprised 122 participants: 16 COPD patients utilizing inhaled fluticasone, 16 COPD patients utilizing inhaled budesonide, and 90 individuals in the control group. The mean age of the study participants was 72.79 years; the mean age of the fluticasone group was 74.69 years, the mean age of the budesonide group was 73.19 years, and the mean age of the control group was 72.38 years. The groups exhibit no significant difference for osteoporosis (p>0.05). No significant difference was seen between the groups for the duration and intensity of ICS use (p>0.05). Conclusion: In individuals with COPD, the administration of budesonide and fluticasone as inhaled corticosteroid options has not elevated the risk of osteoporosis.
- Open Access
- 3 November 2025
- Published by The European Research Journal in The European Research Journal
- Vol. 11 (6) , 1176-1183
Alteration in TSH levels during Ramadan in non fasting levothyroxine treated patients living with fasting family members
Objectives: During Ramadan, lifestyle changes may affect thyroid function not only in fasting individuals but also in those who do not fast. This study examined the impact of Ramadan-related behavioral shifts on thyroid-stimulating hormone (TSH) levels in patients receiving stable levothyroxine therapy. Methods: This observational before-and-after study, conducted between January 2023 and January 2024, included 116 hypothyroid patients on stable levothyroxine (LT4) therapy. Serum TSH, free thyroxine (fT4), and free triiodothyronine (fT3) levels were measured one month before and within one week after Ramadan. Patients were categorized as fasting or non-fasting, and completed a structured questionnaire regarding medication timing, fasting behavior, and lifestyle changes. Linear regression analysis was used to identify predictors of post-Ramadan TSH changes. Results: TSH levels significantly increased after Ramadan in the overall cohort (mean±SD: 3.03±3.24 vs. 4.77±7.83 mU/L; P=0.028), while fT3 and fT4 levels remained unchanged (P=0.14 and P=0.72, respectively). Among fasting patients (n=72), TSH rose from 3.26±3.26 to 4.80±8.58 mU/L (P=0.47), whereas non-fasting patients (n=44) showed a significant increase from 2.65±3.21 to 4.73±6.51 mU/L (P=0.006). Polypharmacy was associated with increased odds of post-Ramadan TSH elevation (OR=2.67, 95% CI: 1.25–5.73, P=0.01). Among non-fasting patients, those who reported changes in sleep or meal patterns during Ramadan (n=28) experienced a significantly higher increase in TSH compared to those without such changes (ΔTSH: 2.47±3.88 vs. 0.81±2.12 mU/L, P=0.02). Conclusions: Patients receiving LT4 therapy who do not fast during Ramadan may still exhibit significant TSH variability, likely due to behavioral and circadian disruptions. These findings emphasize the importance of proactive monitoring and targeted education for all hypothyroid patients during Ramadan, irrespective of fasting status.
- 3 November 2025
- Published by The European Research Journal in The European Research Journal
- Vol. 11 (6) , 1176-1183
Open AccessAlteration in TSH levels during Ramadan in non fasting levothyroxine treated patients living with fasting family members
Objectives: During Ramadan, lifestyle changes may affect thyroid function not only in fasting individuals but also in those who do not fast. This study examined the impact of Ramadan-related behavioral shifts on thyroid-stimulating hormone (TSH) levels in patients receiving stable levothyroxine therapy. Methods: This observational before-and-after study, conducted between January 2023 and January 2024, included 116 hypothyroid patients on stable levothyroxine (LT4) therapy. Serum TSH, free thyroxine (fT4), and free triiodothyronine (fT3) levels were measured one month before and within one week after Ramadan. Patients were categorized as fasting or non-fasting, and completed a structured questionnaire regarding medication timing, fasting behavior, and lifestyle changes. Linear regression analysis was used to identify predictors of post-Ramadan TSH changes. Results: TSH levels significantly increased after Ramadan in the overall cohort (mean±SD: 3.03±3.24 vs. 4.77±7.83 mU/L; P=0.028), while fT3 and fT4 levels remained unchanged (P=0.14 and P=0.72, respectively). Among fasting patients (n=72), TSH rose from 3.26±3.26 to 4.80±8.58 mU/L (P=0.47), whereas non-fasting patients (n=44) showed a significant increase from 2.65±3.21 to 4.73±6.51 mU/L (P=0.006). Polypharmacy was associated with increased odds of post-Ramadan TSH elevation (OR=2.67, 95% CI: 1.25–5.73, P=0.01). Among non-fasting patients, those who reported changes in sleep or meal patterns during Ramadan (n=28) experienced a significantly higher increase in TSH compared to those without such changes (ΔTSH: 2.47±3.88 vs. 0.81±2.12 mU/L, P=0.02). Conclusions: Patients receiving LT4 therapy who do not fast during Ramadan may still exhibit significant TSH variability, likely due to behavioral and circadian disruptions. These findings emphasize the importance of proactive monitoring and targeted education for all hypothyroid patients during Ramadan, irrespective of fasting status.